Structural determinants of imidazoacridinones facilitating antitumor activity are crucial for substrate recognition by ABCG2

Molecular Pharmacology

Volumn 75, Issue 5, 2009, Pages 1149-1159

  Bram, Eran E ^a   Adar, Yamit ^a   Mesika, Nufar ^a   Sabisz, Michal ^b   Skladanowski, Andrzej ^b   Assaraf, Yehuda G ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; ARGININE; BREAST CANCER RESISTANCE PROTEIN; FUMITREMORGIN C; GLYCINE; HYDROXYL GROUP; IMIDAZOACRIDINONE DERIVATIVE; SYMADEX; THREONINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; T CELL LEUKEMIA;

ACRIDINES; AMINOACRIDINES; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 66049093214     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.054791     Document Type: Article

References (46)

1. Al-Shawi MK, Polar MK, Omote H, and Figler RA (2003) Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein. J Biol Chem 278:52629-52640. (Pubitemid 38035860)
2. Alami N, Paterson J, Belanger S, Juste S, Grieshaber CK, and Leyland-Jones B (2007) Comparative cytotoxicity of C-1311 in colon cancer in vitro and in vivo using the hollow fiber assay. J Chemother 19:546-553.
3. Assaraf YG (2006) The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 9:227-246.
4. Assaraf YG (2007) Molecular basis of antifolate resistance. Cancer Metastasis Rev 26:153-181. (Pubitemid 46452189)
5. Bates SE, Medina-Pérez WY, Kohlhagen G, Antony S, Nadjem T, Robey RW, and Pommier Y (2004) ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins. J Pharmacol Exp Ther 310:836-842. (Pubitemid 38988932)
6. Belmont P, Bosson J, Godet T, and Tiano M (2007) Acridine and acridone derivatives, anticancer properties and synthetic methods: where are we now? Anticancer Agents Med Chem 7:139-169.
7. Borgnia MJ, Eytan GD, and Assaraf YG (1996) Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem 271:3163-3171. (Pubitemid 26055617)
8. Borst P and Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-592.
9. Bram E, Ifergan I, Shafran A, Berman B, Jansen G, and Assaraf YG (2006) Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol 58:826-834. (Pubitemid 44351264)
10. Bram EE, Ifergan I, Grimberg M, Lemke K, Skladanowski A, and Assaraf YG (2007) C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells. Biochem Pharmacol 74:41-53. (Pubitemid 46802491)
11. Burger AM, Double JA, Konopa J, and Bibby MC (1996) Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer. Br J Cancer 74:1369-1374. (Pubitemid 26370726)
12. Cholody WM, Martelli S, and Konopa J (1990a) 8-Substituted 5-[(aminoalkyl) amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents. Synthesis and biological activity. J Med Chem 33:2852-2856. (Pubitemid 20312155)
13. Cholody WM, Martelli S, Paradziej-Lukowicz J, and Konopa J (1990b) 5-[(Aminoalkyl) amino]imidazo[4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activity. J Med Chem 33:49-52. (Pubitemid 20038169)
14. Clark R, Kerr ID, and Callaghan R (2006) Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter. Br J Pharmacol 149:506-515. (Pubitemid 44658511)
15. Deeley RG, Westlake C, and Cole SP (2006) Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86:849-899. (Pubitemid 44033384)
16. Doyle LA and Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340-7358. (Pubitemid 37487163)
17. Dziegielewski J, Slusarski B, Konitz A, Skladanowski A, and Konopa J (2002) Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity. Biochem Pharmacol 63:1653-1662. (Pubitemid 34458004)
18. Ebert B, Seidel A, and Lampen A (2005) Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 26:1754-1763. (Pubitemid 41487991)
19. Ebert B, Seidel A, and Lampen A (2007) Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. Toxicol Sci 96:227-236. (Pubitemid 46436705)
20. Eytan GD, Regev R, and Assaraf YG (1996) Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis. J Biol Chem 271:3172-3178. (Pubitemid 26055618)
21. Goodman K, Duncan K, Locniskar A and Ajami A (2008) SymadexTM, a FLT3 kinase inhibitor, is metabolized by aldehyde oxidase. FASEB J 22:920.5.
22. Hyzy M, Bozko P, Konopa J, and Skladanowski A (2005) Antitumour imidazoacridone C-1311 induces cell death by mitotic catastrophe in human colon carcinoma cells. Biochem Pharmacol 69:801-809. (Pubitemid 40248622)
23. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 99:15649-15654. (Pubitemid 35403986)
24. Jonker JW, Musters S, Vlaming ML, Plösch T, Gooijert KE, Hillebrand MJ, Rosing H, Beijnen JH, Verkade HJ, and Schinkel AH (2007) Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX. Am J Physiol Cell Physiol 292:C2204-C2212. (Pubitemid 47080514)
25. Kusnierczyk H, Cholody WM, Paradziej-Lukowicz J, Radzikowski C and Konopa J (1994) Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones. Arch Immunol Ther Exp (Warsz) 42:415-423.
26. Modok S, Mellor HR, and Callaghan R (2006) Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 6:350-354. (Pubitemid 44026037)
27. Mueller SO, Schmitt M, Dekant W, Stopper H, Schlatter J, Schreier P, and Lutz WK (1999) Occurrence of emodin, chrysophanol and physcion in vegetables, herbs and liquors. Genotoxicity and anti-genotoxicity of the anthraquinones and of the whole plants. Food Chem Toxicol 37:481-491. (Pubitemid 29306913)
28. Nakanishi T, Karp JE, Tan M, Doyle LA, Peters T, Yang W, Wei D, and Ross DD (2003) Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin Cancer Res 9:3320-3328. (Pubitemid 37082726)
29. Poindessous V, Koeppel F, Raymond E, Comisso M, Waters SJ, and Larsen AK (2003) Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin. Clin Cancer Res 9:2817-2825. (Pubitemid 36842128)
30. Polgar O, Robey RW, and Bates SE (2008) ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol 4:1-15.
31. Rabindran SK, Ross DD, Doyle LA, Yang W, and Greenberger LM (2000) Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60:47-50. (Pubitemid 30058728)
32. Rajendra R, Gounder MK, Saleem A, Schellens JH, Ross DD, Bates SE, Sinko P, and Rubin EH (2003) Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res 63:3228-3233. (Pubitemid 36735876)
33. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, and Bates SE (2003) Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89:1971-1978. (Pubitemid 37533279)
34. Ross DD, Karp JE, Chen TT, and Doyle LA (2000) Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 96:365-368.
35. Sarkadi B, Homolya L, Szakács G, and Váradi A (2006) Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86:1179-1236. (Pubitemid 44521651)
36. Shafran A, Ifergan I, Bram E, Jansen G, Kathmann I, Peters GJ, Robey RW, Bates SE, and Assaraf YG (2005) ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. Cancer Res 65:8414-8422. (Pubitemid 41330608)
37. Sharom FJ (2008) ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9:105-127.
38. Stam RW, van den Heuvel-Eibrink MM, den Boer ML, Ebus ME, Janka-Schaub GE, Allen JD, and Pieters R (2004) Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. Leukemia 18:78-83. (Pubitemid 38159442)
39. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, and Sauerbrey A (2002) BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16:1443-1447.
40. Takagi K, Dexheimer TS, Redon C, Sordet O, Agama K, Lavielle G, Pierré A, Bates SE, and Pommier Y (2007) Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters. Mol Cancer Ther 6:3229-3238.
41. Topcu Z (2001) DNA topoisomerases as targets for anticancer drugs. J Clin Pharm Ther 26:405-416. (Pubitemid 34205966)
42. Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, and Sullivan DM (2006) ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood 108:3881-3889.
43. van den Heuvel-Eibrink MM, Wiemer EA, Prins A, Meijerink JP, Vossebeld PJ, van der Holt B, Pieters R, and Sonneveld P (2002) Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia 16:833-839. (Pubitemid 34537555)
44. Velamakanni S, Janvilisri T, Shahi S, and van Veen HW (2008) A functional steroid-binding element in an ATP-binding cassette multidrug transporter. Mol Pharmacol 73:12-17. (Pubitemid 350294192)
45. Wang M (2007) Extending the good diet, good health paradigm: modulation of breast cancer resistance protein (BCRP) by flavonoids. Toxicol Sci 96:203-205. (Pubitemid 46432016)
46. Yoshikawa M, Ikegami Y, Hayasaka S, Ishii K, Ito A, Sano K, Suzuki T, Togawa T, Yoshida H, Soda H, et al. (2004) Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer 110:921-927. (Pubitemid 38758521)